Sanxin Medical (300453.SZ) plans to pay 1.5 yuan for 10 shares to be deducted from interest on April 25

Sanxin Medical (300453.SZ) announced that the company's 2023 equity distribution plan: a cash dividend of 1.5 yuan (tax included) will be distributed to all shareholders for every 10 shares; the exclusion date is: April 25, 2024.

Zhitong FinanceApr 18 22:18

Sanxin Medical (300453.SZ): Net profit of 53.618,700 yuan in the first quarter increased 19.72% year-on-year

Gelonghui, April 16, 丨 Sanxin Medical (300453.SZ) released its report for the first quarter of 2024, with operating income of 331 million yuan, up 21.34% year on year; net profit attributable to shareholders of listed companies was 53.618,700 yuan, up 19.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 467.935 million yuan, up 28.61% year on year; basic earnings per share were 0.1032 yuan.

Gelonghui FinanceApr 16 20:49

Express News | Sanxin Medical: The company's hemodialysis product collection and bid had little impact on the factory price

BreakingsApr 10 09:54

Jiangxi Shengdankang, a wholly-owned subsidiary of Sanxin Medical (300453.SZ), received a medical device production license

Sanxin Medical (300453.SZ) announced that Jiangxi Shengdankang Medical Technology Co., Ltd. (“Jiangxi Shengdankang”), a wholly-owned subsidiary of the company, has obtained a “Medical Device Production License” issued by the Jiangxi Drug Administration. According to the announcement, Jiangxi Shengdankang specializes in the development of products related to chronic kidney disease medical equipment, traditional Chinese medicine colon dialysis, traditional Chinese medicine and device combinations, and sales and service of medical device products.

Zhitong FinanceApr 9 18:49

Sanxin Medical (300453.SZ): The products of the holding subsidiary passed the innovative medical device review

Sanxin Medical (300453.SZ) announced that recently, Jiangxi Colectin Biotechnology Co., Ltd. (hereinafter referred to as “colevipid”), a holding subsidiary of the company, received the “Jiangxi Province Class II Medical Device Innovative Product Registration Review Results Form” issued by the Jiangxi Drug Administration. The “Leakage Monitor”, a product independently developed by Colectin, was approved for the registration review of Class II medical device innovation products in Jiangxi Province.

Zhitong FinanceApr 8 08:13

Sanxin Medical (300453) 2023 Report Review: Collection Implementation Accelerates Localization and Focus on Extending the Entire Nephrology Industry Chain

Incident: The company released the 2023 annual report. In 2023, it achieved operating income of 1,300 million yuan, a year-on-year decrease of 2.69%; net profit to mother was 207 million yuan, an increase of 11.92% over the previous year; net profit not attributable to mother1

國元證券Apr 2 00:00